Arthritis Drug Of Japan’s Chugai, Roche Shows Well In Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
A drug developed by Japan's Chugai Pharmaceutical and Switzerland's Roche Holdings is showing favorable results midway through a Phase III study for reducing joint damage from rheumatoid arthritis. The drug is Actemra (tocilizumab), the subject of a delay by the U.S. FDA in reviewing it for possible approval. FDA wanted more data related to manufacturing and labeling, according to Roche. Researchers said the ongoing study shows Actemra to be effective in slowing the progression of bone erosion when used over a four-week period with methotrexate. The drug is expected to be a billion-dollar seller for the two drug makers once approved. (Click here for more